Findings from COX 2 studies are releasedBMJ 2005; 330 doi: https://doi.org/10.1136/bmj.330.7488.381-a (Published 17 February 2005) Cite this as: BMJ 2005;330:381
- Scott Gottlieb
- New York
Results from recent studies that raised concerns about the cardiovascular safety of cyclo-oxygenase-2 (COX 2) inhibitors have been made available early, in advance of hearings on the drug class by the US Food and Drug Administration.
All the studies have been published online in the New England Journal of Medicine (http://nejm.org/), and the journal lifted its normal embargo date for the studies because of what it described as the “possible public health implications.”
The results come immediately before a three-day hearing looking into the benefits and risks of COX 2 inhibitors …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial